IL13RA2 and glioblastoma: In one patient with recurrent multifocal glioblastoma, intracranial administration of IL-13Rα2-targeted CAR T cells resulted in the regression of all intracranial and spinal lesions, but subsequent relapse was in IL-13Rα2-negative tumors [10].